Shots:
The life science industry saw high deal activity in 2021 staying in the range of an even busier 2020.
Fourth-quarter 2021 set the tone with Recursion’s development and commercialization deal with Roche and Genentech for a total value of $12.7B, followed by Poseida Therapeutics’ development and commercialization deal with Takeda for $3.73B.
This article is based on the 2021…
